A statewide initiative backed by Microsoft will bring new digital education to the University of Houston campus. Photo via UH.edu

The University of Houston College of Technology has been selected for a new initiative to bring digital and technical skills to students and the workforce.

Microsoft's Accelerate program is a part of the tech giant's Global Skills Initiative, a multimillion-dollar investment seeking to increase digital skills to equip 25 million people worldwide by the end of 2020, according to the website.

"The University of Houston is proud to be part of an effort to prepare strong professionals and leaders in Texas who think innovatively and are equipped with next-generation skills to be successful," says Paula Myrick Short, senior vice president for academic affairs and provost at UH, in a press release. "The College of Technology is well-positioned to strengthen this workforce pipeline and create a stronger Texas."

Along with Microsoft, UH is also working with the Texas Education Agency to develop courses that will teach a variety of tech skills, including STEM engagement for students in K-12, professional development, workforce development for high school and college students, and even parents and professionals seeking opportunities to enhance business and technical skills, according to the release.

"The College of Technology is working with Microsoft to provide Texas communities with resources to create meaningfully unique opportunities," says Dean Anthony Ambler in the release. "From high schools to professionals across the state, our programs transcend the classroom to support workforce creation and upskilling. These activities champion Texas communities with a focus on digital equity among underserved areas that solve problems and improve lives."

The college joins other Texas partners, including STEMuli, The Ion, NASA, the Dallas Independent School District, Bell, Big Thought, Stedman Graham and Associates, Tribute to Valor, National Math and Science Initiative, Dallas Regional Chamber, and the Irving Chamber of Commerce.

"Texans are some of the brightest, most productive people in the world. It is exciting to work to establish a statewide innovation ecosystem to support a sustainable culture of opportunity," says David Crawley, professor of practice with the College of Technology, in the release.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.